Alzheon Inc.
Clinical trials sponsored by Alzheon Inc., explained in plain language.
-
New pill tested to slow Alzheimer's in High-Risk group
Disease control CompletedThis study tested an oral medication called ALZ-801 in 84 people with early Alzheimer's disease who carry a specific genetic risk factor (the APOE4 gene). The main goal was to see if the drug could affect biological markers of Alzheimer's in the blood and brain over two years, an…
Phase: PHASE2 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Apr 04, 2026 06:20 UTC
-
New Alzheimer's pill shows promise in slowing cognitive decline for High-Risk group
Disease control CompletedThis Phase 3 trial tested whether an oral medication called ALZ-801 could slow Alzheimer's progression in people with early-stage disease who carry two copies of the APOE4 gene, which increases risk. 325 participants took either the drug or a placebo twice daily for 78 weeks whil…
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC